Counterfeit and substandard products present a big challenge to any national plan or policy
devised to improve public health. Poor quality drug products are especially a problem in …

In a number of developing countries there is reportedly a high incidence of the availability of
substandard drugs. The majonty of these reports do not contain quantitative data to support …

There is considerable interest in optimizing the therapy for important infections in developing
countries and in making the best treatments readily available and inexpensive. There is also …

Many poor-quality medicines are supplied to patients mainly in developing countries. No
systematic survey on counterfeit medicines has been conducted in Myanmar since 1999 …

Abstract Cambodia's Ministry of Health and the Department of Drugs and Food have been
actively working to reduce the amount of poor quality medicines circulating in the …

Several articles in the press have reported alarming percentages of counterfeit drugs in
developing countries. The present study assessed the quality of anti-infectious drugs in …

Substandard and falsified antimalarial and antibiotic medicines represent a serious problem
for public health, especially in low-and middle-income countries. However, information on …

Objective: There are several independent reports in Tanzania of treatment failures with
commercially available sulphadoxine/pyrimethamine (SP) and amodiaquine (AQ) brands …

Falsified and substandard medicines may undermine the progress toward the Sustainable
Development Goals. The present study investigated the quality of 13 essential medicines in …

Substandard and falsified medicines have severe public health and socioeconomic effects,
especially in low-and middle-income countries. The WHO has emphasized the need for …